Arcus Biosciences (RCUS) announced that quemliclustat, an investigational small molecule CD73 inhibitor, was granted orphan drug designation by the FDA for the treatment of pancreatic cancer.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RCUS:
- Arcus Biosciences treatment of pancreatic cancer granted orphan designation
- Arcus Biosciences Advances Phase 1 Study for Promising Cancer Treatment
- Gilead and Arcus Biosciences’ Promising Oncology Study Update
- Arcus Biosciences’ AB598 Study: A New Frontier in Cancer Treatment
- Gilead and Arcus Advance Promising Colorectal Cancer Study